Implantable medical device

Abstract

The invention provides an implantable medical device which comprises a plurality of hollowed-out supporting frameworks, a plurality of drug-loading first pointed bodies and a plurality of wrapping pieces, the first pointed bodies are fixed to the supporting frameworks, and the wrapping pieces are fixedly connected with the supporting frameworks and fixed to part of the circumferential faces of the first pointed bodies. The wrapping part is attached to part of the peripheral face of the first pointed body, the first pointed body can be fixed, the first pointed body can stably penetrate into the tissue of the inner wall of the lumen of the human body, the first pointed body is effectively prevented from being bent or broken, and the device is stable in structure, safe and durable.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of medical devices, in particular to an implantable medical device. BACKGROUND

[0002] With the improvement of people's living standards, people pay more and more attention to health problems, which include the narrowing, rupture, tumor and other lesions of the body lumen.

[0003] At present, the main treatment method for the above-mentioned diseases is to implant a medical device such as a stent in the body lumen. The stent can improve the treatment effect by expanding at the narrow part of the channel. However, the stent can also cause a series of adverse reactions, such as neointimal hyperplasia and mid-term restenosis. For this reason, a drug stent has been developed. The drug stent is provided with a drug-loaded microneedle on the stent, which can achieve the purpose of drug treatment, prevention of hyperplasia and infection by piercing the tissue. However, the existing drug-loaded microneedle is usually provided separately on the stent, which can cause the drug-loaded microneedle to bend or break when piercing the tissue, affecting its treatment and fixation effect. SUMMARY

[0004] In order to overcome the above technical problems, the present application provides an implantable medical device which can stab into the tissue stably without bending or breaking.

[0005] As conceived above, the technical solution adopted by the present application is to provide an implantable medical device, which comprises a plurality of hollow support skeletons, a plurality of drug-loaded first spikes and a plurality of covering members. The first spikes are fixed to the support skeletons, and the covering members are fixedly connected with the support skeletons and fixed to part of the circumferential surface of the first spikes.

[0006] Preferably, the covering member is fixed to part of the circumferential surface of the proximal end of the first spike.

[0007] Preferably, the covering member covers the entire circumferential surface of the proximal end of the first spike.

[0008] Preferably, the distal end of the covering member is provided with an opening, and the distal end of the first spike is exposed from the opening.

[0009] Preferably, the covering member has a through hole, and part of the first spike is exposed from the through hole.

[0010] Preferably, a connecting body is arranged between the covering member and the support skeleton, and the connecting body is fixedly connected with the covering member and the support skeleton, respectively.

[0011] Preferably, the connecting body is attached to part of the surface of the support skeleton.

[0012] Preferably, the support framework comprises a wave coil and a connecting rod fixedly connected with the wave coil, and the connecting body surrounds the wave coil or the connecting rod; or the connecting body partially covers the wave coil or the connecting rod.

[0013] Preferably, a line connecting the center points of the distal end and the proximal end of the first pointed body extends along the radial direction of the support framework.

[0014] Preferably, the implantable medical device further comprises a covering film arranged on the support framework, and a plurality of drug-loaded second pointed bodies are arranged on the covering film.

[0015] The present application has at least the following beneficial effects:

[0016] The plant medical device of the present application can fix the first pointed body by attaching the partial circumferential surface of the first pointed body to the covering member, so that the first pointed body can be stably inserted into the tissue of the inner wall of the lumen of the human body, and the first pointed body can be effectively prevented from being bent or broken, and the structure is stable, safe and durable. BRIEF DESCRIPTION OF DRAWINGS

[0017] Figure 1 is a perspective view of an embodiment of the implantable medical device provided by the present application;

[0018] Figure 2 is Figure 1 is a partial enlarged view of part A of the implantable medical device shown in the figure;

[0019] Figure 3 is Figure 2 is a sectional view of the first embodiment of the B-B line of the implantable medical device shown in the figure;

[0020] Figure 4 is Figure 2 is a sectional view of the second embodiment of the B-B line of the implantable medical device shown in the figure;

[0021] Figure 5 is Figure 2 is a sectional view of the third embodiment of the B-B line of the implantable medical device shown in the figure;

[0022] Figure 6 is Figure 2 is a sectional view of the fourth embodiment of the B-B line of the implantable medical device shown in the figure;

[0023] Figure 7 is Figure 1 is a top view of the implantable medical device shown in the figure;

[0024] Figure 8 is Figure 7 is a partial enlarged view of part C of the implantable medical device shown in the figure;

[0025] Figure 9 is a perspective view of a second embodiment of the implantable medical device provided by the present application;

[0026] Figure 10 is a partial enlarged view of a D portion of the implantable medical device shown in Figure 9

[0027] Figure 11 is a sectional view along the line E-E shown in Figure 10

[0028] Figure 12 is a top view of the implantable medical device shown in Figure 9

[0029] Figure 13 is a partial enlarged view of a F portion of the implantable medical device shown in Figure 12

[0030] Figure 14 is a combination view of the implantable medical device provided by the present application and a sheath and a balloon.

[0031] BRIEF DESCRIPTION OF DRAWINGS100-implantable medical device; 1-wave coil; 2-connecting rod; 3-first pointed body; 31-distal end; 32-proximal end; 4-covering member; 41-connector; 42-through hole; 43-opening; 5-coated film; 6-second pointed body; 7-balloon; 8-sheath; 9-hollow. DETAILED DESCRIPTION

[0032] The implantable medical device provided by the present application will be described in detail below with reference to the accompanying drawings. It can be understood that the described embodiments are only some embodiments of the present application, not all embodiments, and the present application can be implemented in many other ways different from those described herein.

[0033] Unless otherwise defined, all technical and scientific terms used in the specification have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used in the specification is for describing particular embodiments only and is not intended to be limiting of the application.

[0034] It should be noted that all directional indications, e.g., top, bottom, left, right, back, front, under, above, upper, lower, clockwise, counterclockwise, horizontal, vertical, etc., are used only for the purpose of explanation and are not to be construed as limiting the present application.

[0035] ​​​In addition, the descriptions such as "first", "second" and the like in the present application are only for the purpose of description, and cannot be understood as indicating or implying the relative importance of the technical features indicated, or implying the number of the technical features indicated. Therefore, the features defined as "first", "second" can explicitly or implicitly include at least one of the features. In the description of the present application, the meaning of "a plurality of" is at least two, such as two, three, etc., unless otherwise specifically limited.

[0036] The technical solutions of various embodiments of the present application can be combined with each other, but must be based on the fact that a person skilled in the art can realize it, and when the combination of technical solutions appears contradictory or unachievable, it should be considered that the combination of technical solutions does not exist, nor is it within the protection scope required by the present application.

[0037] In the present application, the axial direction refers to the direction parallel to the line connecting the distal center and the proximal center of the assembly; the radial direction refers to the direction perpendicular to the above-mentioned axial direction.

[0038] As shown in Figures 1 to 3 , Figure 6 and Figure 7 , an embodiment of the present application provides an implantable medical device 100, which comprises a support framework with a plurality of hollows 9, a plurality of drug-loaded first spikes 3, and a plurality of covering members 4, the first spikes 3 are fixedly connected with the support framework, the covering members 4 are fixedly connected with the support framework, and the covering members 4 are fixed to part of the peripheral surface of the first spikes 3.

[0039] Preferably, the support framework is used to support the human body lumen passage to prevent its stenosis, which can be a lumen implant or other implant, such as a one-way valve used in lung volume reduction surgery.

[0040] Preferably, the support framework is preferably a tubular structure, such as a cylindrical structure, an elliptical cylindrical structure, a frustum structure, etc. In the present embodiment, the support framework is preferably a cylindrical structure, and in other embodiments, the support framework can also be a combination of one or more of the above structures.

[0041] Preferably, the support framework comprises at least two wave coils 1 and connecting rods 2 for connecting adjacent two wave coils 1, as shown in Figure 1 The connecting rod 2 is located between the adjacent two wave coils 1, the wave coil 1 is composed of a Z-shaped wave, and other structures can also be used, which will not be described here. Further, one end of the connecting rod 2 is fixedly connected with the wave coil 1 located at the one end, and the other end of the connecting rod 2 is fixedly connected with the wave coil 1 located at the other end, thereby playing a connecting and fixing role for the adjacent two wave coils 1. The wave coil 1 and the connecting rod 2 can be fixedly welded with each other, or can be integrally formed, etc., which will not be described here.

[0042] Furthermore, the wave coil 1 and / or connecting rod 2 are made of biocompatible materials, such as nickel-titanium alloy, iron, magnesium alloy, stainless steel, polylactic acid, etc., which can be selected and set as needed, so they will not be described in detail here.

[0043] Preferably, a plurality of first pointed bodies 3 are fixed to the supporting skeleton. Specifically, the plurality of first pointed bodies 3 can be disposed at any position on the outer surface of the supporting skeleton, or at any position on the inner surface of the supporting skeleton, or simultaneously at any position on both the inner and outer surfaces of the supporting skeleton. It is understood that, according to common knowledge of those skilled in the art, the outer surface of the supporting skeleton refers to the surface that contacts the tissue after the device is implanted, and the inner surface of the supporting skeleton refers to the surface opposite to the outer surface. When the first pointed body 3 is disposed on the outer surface of the supporting skeleton, it can penetrate the tissue, and the degraded medication on the surface of the first pointed body 3 can be introduced into the tissue, achieving a therapeutic effect. When the first pointed body 3 is disposed on the inner surface of the supporting skeleton, the first pointed body 3 is in a tubular medium, such as urine or water. After the surface of the first pointed body 3 contacts the tubular medium, it degrades, allowing the degraded medication to flow into the tubular medium, thereby achieving a therapeutic effect.

[0044] Furthermore, such as Figure 2 As shown, in a preferred embodiment, a plurality of first pointed bodies 3 are distributed on the outer surface of the supporting skeleton. See also... Figure 3 Let wave circle 1 represent the supporting skeleton. The end of the first pointed body 3 closest to the supporting skeleton is the proximal end 32, and the end furthest from the supporting skeleton is the distal end 31. The cross-sectional area of ​​the distal end 31 of the first pointed body 3 is smaller than that of its proximal end 32, thereby ensuring that the distal end 31 of the first pointed body 3 is needle-shaped and can penetrate the tissue. Furthermore, the first pointed body 3 is preferably a cone, but it can also be a polygonal pyramid, etc. The shape of the first pointed body 3 can be selected and set as needed, and will not be elaborated here.

[0045] Preferably, a plurality of first pointed bodies 3 may be disposed on the wave coil 1, or on the connecting rod 2, or simultaneously on the wave coil 1 and the connecting rod 2.

[0046] In one embodiment, the covering 4 is fixedly connected to the supporting frame.

[0047] Specifically, the connection between the covering 4 and the supporting frame can be as follows: the covering 4 is fixedly connected to the wave coil 1, or fixedly connected to the connecting rod 2, or fixedly connected to both the wave coil 1 and the connecting rod 2, etc.

[0048] Preferably, such as Figure 3 As shown, the near-end bottom surface of the covering 4 is directly fixedly connected to the wave ring 1. The two can be fixedly connected by welding, bonding or other methods, or by integral molding.

[0049] More preferably, as shown in Figure 4 As shown in

[0050] More preferably, as shown in Figure 5 As shown in

[0051] Preferably, the connecting body 41 and the covering member 4 can be made of stable and non-degradable materials, such as metals and non-degradable non-metallic materials, and preferably made of one or more of PVPK90 (povidone), PEEK (polyether ether ketone), PMMA (polymethyl methacrylate), and PTFE (polytetrafluoroethylene). The connecting body 41 can also be composed of multiple layers, and each layer is made of one of the above-mentioned materials, so as to meet the different structure and strength requirements of the connecting body 41.

[0052] In one embodiment, the covering member 4 is fixed to a part of the circumferential surface of the first pointed body 3. The "circumferential surface" refers to the surface connecting the proximal end surface and the distal end point of the first pointed body 3. The covering member 4 can be annular and cover a part of the circumferential surface of the first pointed body 3 in the radial direction of the first pointed body 3. The covering member 4 can also be plate-shaped or arc-shaped and cover only a part of the circumferential surface of the first pointed body 3.

[0053] As shown in Figures 3 to 5 The covering member 4 covers the proximal circumferential surface of the first pointed body 3 and is provided with an opening 43 at the distal end, exposing the distal end 31 of the first pointed body 3. Thus, the covering member 4 can play a role in strengthening the structure of the first pointed body 3 and preventing it from breaking.

[0054] Each first pointed body 3 can be fixed with only one covering member 4, or can be fixed with multiple covering members 4 at the same time. When multiple covering members 4 are fixed to the circumferential surface of one first pointed body 3, the multiple covering members 4 can be attached to the circumferential surface of the first pointed body 3 in sequence, with the first and last covering members 4 being adjacent to each other, or the multiple covering members 4 can be arranged on the circumferential surface of the first pointed body 3 with a spacing between them.

[0055] The shape of the covering member 4 needs to be adapted to the shape of the first pointed body 3. For example, when the first pointed body 3 is a circular cone, the covering member 4 is preferably a circular truncated cone. For example, when the first pointed body 3 is a polygonal cone, the covering member 4 is preferably a polygonal truncated cone. Through the above limitation, the contact between the first pointed body 3 and the covering member 4 can be more closely and firmly, and the overall structural stability can be enhanced.

[0056] The covering member 4 can be in the shape of a frame, as shown in Figures 3 to 5 The covering member 4 has a cavity, and an opening 43 at the distal end of the cavity. The first pointed body 3 is formed in the covering member 4, the proximal end 32 of the first pointed body 3 is accommodated in the covering member 4, and the distal end 31 of the first pointed body 3 is exposed from the opening 43, so that the distal end 31 of the first pointed body 3 can be in contact with the tissue smoothly to penetrate the tissue and play a therapeutic role on the tissue.

[0057] In an embodiment, as shown in Figure 6 The covering member 4 has a plurality of through holes 42, and the first pointed body 3 is exposed from the through holes 42. On the one hand, the connection stability between the first pointed body 3 and the covering member 4 can be enhanced. On the other hand, the first pointed body 3 exposed from the through holes 42 can be in full contact with the tissue to achieve a therapeutic effect on the tissue. Only one through hole 42 can be provided. The user can choose to set according to the needs, which is not specifically limited here.

[0058] In an embodiment, as shown in Figure 7 and Figure 8 The line y2 connecting the center points of the distal end 31 and the proximal end 32 of the first pointed body 3 extends along the radial direction y1 of the support framework.

[0059] Preferably, as shown in Figure 7 and Figure 8 The first pointed body 3 is a circular cone or a polygonal cone, and the first pointed body 3 has a central axis y2 connecting the center points of the distal end 31 and the proximal end 32 of the first pointed body 3. The central axis y2 of the first pointed body 3 extends along the radial direction y1 of the support framework.

[0060] The above structure can make the radial support force or balloon expansion force of the first pointed body 3 from the support framework and the central axis y2 of the first pointed body 3 in one direction, so that the pressure of the head end of the first pointed body 3 penetrating the tissue is maximized, and the first pointed body 3 is more easily penetrated into the tissue. At the same time, the force in the direction perpendicular to the central axis y2 of the first pointed body 3 is small, thereby preventing the first pointed body 3 from breaking.

[0061] In an embodiment, referring to Figure 9 and Figure 10The implantable medical device 100 further comprises a film 5 arranged on the supporting framework, and the film 5 is provided with a plurality of second pointed bodies 6 loaded with drugs, and the second pointed bodies 6 are in the shape of a cone or a multi-prism.

[0062] Preferably, at least part of the outer wall and / or at least part of the inner wall of the supporting framework is provided with the film 5. When the film 5 covers at least part of the outer wall or at least part of the inner wall of the supporting framework, the first pointed bodies (not shown in the figure) can be located on the opposite sides of the supporting framework with the film 5, or both are located on the same side of the supporting framework. When the film 5 covers at least part of the outer wall and at least part of the inner wall of the supporting framework, the first pointed bodies pass through the film 5. The surface of the film 5 is provided with a plurality of second pointed bodies 6 loaded with drugs and spaced from each other. In other embodiments, the surface of the film 5 is not provided with the second pointed bodies 6. The film 5 is made of biocompatible materials such as ePTFE (a garment fabric made of a polytetrafluoroethylene microporous film and a common fabric layer), PET (polyethylene terephthalate), silk fibroin, silicone, etc. The film 5 is fixed to the inner surface of the supporting framework, or the outer surface of the supporting framework, or both the inner surface and the outer surface of the supporting framework. Specifically, the film 5 is fixed to the inner surface of the wave coil 1, or the outer surface of the wave coil 1, or both the inner surface and the outer surface of the wave coil 1.

[0063] Further, when the second pointed bodies 6 and the film 5 are made of the same material such as silk fibroin, etc., the second pointed bodies 6 and the film 5 can be integrally formed, so that the connection between the two can be more firm, and the process steps and difficulty can be reduced, and the cost can be reduced.

[0064] Further, the second pointed bodies 6 can be arranged on the outer surface of the film 5, or on the inner surface of the film 5, or on both the inner surface and the outer surface of the film 5. Here, the outer surface of the film 5 refers to the surface of the film 5 that does not contact the outer wall of the supporting framework, and the inner surface of the film 5 refers to the surface of the film 5 that is located in the inner cavity of the supporting framework and does not contact the inner wall of the supporting framework.

[0065] Preferably, as shown in Figure 12 and Figure 13 When the second pointed bodies 6 are arranged on the film 5, the height h1 of the second pointed bodies 6 is less than the thickness h2 of the supporting framework, so that the supporting framework can play a shielding and protecting role on the second pointed bodies 6, preventing damage such as breakage of the second pointed bodies 6 when piercing into the tissue.

[0066] Further, referring to Figure 11The covering film 5 can have a covering part 51 with an opening 511, and the inside of the covering part 51 forms a covering space, the proximal end 61 of the second pointed body 6 is accommodated in the covering space, and the opening 511 area of the covering space is smaller than the proximal end 61 area of the second pointed body 6, so that the proximal end 61 of the second pointed body 6 is movably limited in the covering space and cannot move out of the opening 511, to realize the connection of the second pointed body 6 and the covering part 51, and the second pointed body 6 smoothly penetrates into the tissue. It should be noted that the proximal end 61 is the end of the second pointed body 6 close to the covering film 5.

[0067] Further, the solvent of the raw material liquid of the first pointed body 3 and the second pointed body 6 is water, and the solute is at least one of chitosan, sodium alginate, polyethylene glycol, PLGA (polylactic acid-hydroxy acid), PCL (polycaprolactone), PMMA (polymethyl methacrylate), PGA (polyglycolic acid), PLA (polylactic acid), PEA (polyether amine), gelatin, hyaluronic acid, silk fibroin, etc., and a degradable material is preferably selected. The first pointed body 3 and the second pointed body 6 can further disperse liposomes prepared from phosphatidylcholine and cholesterol. The raw material liquid and the liposomes of the first pointed body 3 and the second pointed body 6 can carry different drugs. The added drugs are for preventing proliferation, treatment and antibacterial, etc. Common drugs are paclitaxel, rapamycin and its derivatives (such as sirolimus, zotarolimus, everolimus, tacrolimus and pimecrolimus), amine-coupled polyurethane (SA-PU) polymer, etc.

[0068] Further, the drug can be added to the raw material liquid to form the first pointed body 3 or the second pointed body 6. The drug content in the raw material liquid of the first pointed body 3 and the second pointed body 6 is 1% to 10%, and further preferably, the drug content in the raw material liquid of the first pointed body 3 and the second pointed body 6 is 1% to 5%. The surface of the first pointed body 3 and the second pointed body 6 can also be coated, and the drug content is 1% to 20%, and further preferably, the drug content is 10% to 15%, and the above-mentioned proportion range is mass percentage. Further, the total drug content of the implant is 30-300ug. The above-mentioned total drug amount and percentage limitation can ensure the treatment effect of the drug and reduce the occurrence of diseases such as intimal hyperplasia.

[0069] Further, in order to meet the clinical needs of the target site, the first spikes 3 and the second spikes 6 can be designed with appropriate height, diameter, number, drug concentration, drug type, degradation rate, etc. For example, the place where the supporting scaffold exerts too much pressure on the tissue is more likely to cause hyperplasia due to stimulation of the tissue, and therefore more first spikes 3 and second spikes 6 can be arranged at this position. For another example, the place where the supporting scaffold contacts the tissue is subjected to shearing force, and therefore is more likely to cause hyperplasia or form granuloma, and therefore more drug-loaded first spikes 3 and second spikes 6 can be arranged to achieve a certain amount of drugs to achieve the effect of preventing hyperplasia and granuloma.

[0070] Further, a plurality of first spikes 3 and second spikes 6 can be arranged on the same implant medical device 100, and the plurality of first spikes 3 and second spikes 6 can have different height, diameter, number, drug concentration, degradation rate, etc., so as to meet different needs of different parts and expand the application range of the implant medical device.

[0071] Further, a plurality of first spikes 3 and second spikes 6 can be arranged on the supporting scaffold, and the plurality of first spikes 3 and second spikes 6 can carry different drugs, so as to achieve the treatment of different diseases. The user can set according to the needs, which will not be described here.

[0072] Further, as shown in FIG. 1, the first spikes 3 and the second spikes 6 can be arranged on the supporting scaffold in a staggered manner. Figure 14As shown, when the implantable medical device 100 is used for tracheal or bronchial stenosis, the support skeleton is first pressed to the surface of the balloon 7, and then loaded into the sheath tube 8 together. To ensure that the first sharp body 3 and the second sharp body 6 are not damaged when loaded into the sheath tube 8, the distance between the tip of the first sharp body 3 and the second sharp body 6 and the inner wall of the sheath tube 8 is L, wherein 0.1mm≤L≤0.5mm, so that the first sharp body 3 and the second sharp body 6 can be avoided when assembling the sheath tube 8, or the profile of the sheath tube 8 is too large to cause some patients to be unsuitable. Then under the guidance of the guide wire, the part of the sheath tube 8 loaded with the implantable medical device is transported to the target position, liquid is injected into the balloon 7, and the pressure is increased to 16 to 26 atmospheres, so that the support skeleton starts to expand under the pushing action of the balloon 7, and then the first sharp body 3 and the second sharp body 6 pierce into the tissue. At this time, the entire first sharp body 3 and the second sharp body 6 can be selected to pierce into the tissue, or the first sharp body 3 and the second sharp body 6 can be partially pierced into the tissue. If the support skeleton is a degradable material and the degradation rate is greater than the degradation rate of the first sharp body 3 and the second sharp body 6, then after degradation, there is no compression to the tissue, reducing the risk of subsequent tissue proliferation, and under the action of the covering piece 4, the first sharp body 3 can be effectively prevented from breaking or bending, so that the first sharp body 3 stably pierces into the tissue. Compared with the existing drug-loaded implantable medical device, the first sharp body 3 and the second sharp body 6 can pierce into the tissue, and as the first sharp body 3 and the second sharp body 6 degrade, the drug is slowly released, prolonging the action time of the drug, and the first sharp body 3 and the second sharp body 6 can carry multiple drugs, different concentrations of drugs, in order to achieve different effects.

[0073] Finally, it should be noted that the above examples are only used to illustrate the technical solutions of the present application, and are not limited thereto. The application scenarios of the implantable medical device are not limited to the fields described herein. Although the present application has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that the technical solutions described in the foregoing embodiments can be modified, or some technical features can be replaced by equivalent ones. These modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present application.

Claims

1. An implantable medical device, characterized in that, It includes a support frame with multiple openings (9), multiple drug-loaded first tips (3) and multiple coverings (4), the first tips (3) are fixed to the support frame, and the coverings (4) are fixedly connected to the support frame and fixed to a portion of the periphery of the first tips (3).

2. The implantable medical device according to claim 1, characterized in that, The covering (4) is fixed to a portion of the circumferential surface of the proximal end (32) of the first tip (3).

3. The implantable medical device according to claim 1, characterized in that, The covering (4) covers the entire circumferential surface of the proximal end (32) of the first tip (3).

4. The implantable medical device according to claim 3, characterized in that, The distal end of the cover (4) is provided with an opening (43), and the distal end (31) of the first tip (3) is exposed from the opening (43).

5. The implantable medical device according to claim 1, characterized in that, The covering (4) has a through hole (42) through which a portion of the first tip (3) is exposed.

6. The implantable medical device according to claim 1, characterized in that, A connector (41) is provided between the covering (4) and the supporting frame, and the connector (41) is fixedly connected to the covering (4) and the supporting frame respectively.

7. The implantable medical device according to claim 6, characterized in that, The connector (41) is attached to a portion of the surface of the support frame.

8. The implantable medical device according to claim 6, characterized in that, The support frame includes a wave coil (1) and a connecting rod (2) fixedly connected to the wave coil (1), and the connecting body (41) surrounds the wave coil (1) or the connecting rod (2); or the connecting body (41) partially covers the wave coil (1) or the connecting rod (2).

9. The implantable medical device according to claim 1, characterized in that, The line (y2) connecting the center points of the distal and proximal ends of the first tip (3) extends radially (y1) along the support skeleton.

10. The implantable medical device according to claim 1, characterized in that, The implantable medical device also includes a membrane (5) disposed on the support frame, and the membrane (5) is provided with a plurality of drug-loaded second tips (6).

Images